Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling.

PURPOSE Radiobiologic modeling is increasingly used to estimate the effects of altered treatment plans, especially for dose escalation. The present article shows how much the linear-quadratic (LQ) (calculated biologically equivalent dose [BED] varies when individual parameters of the LQ formula are varied by +/-20% and by 1%. METHODS Equivalent total doses (EQD2 = normalized total doses (NTD) in 2-Gy fractions for tumor control, acute mucosal reactions, and late complications were calculated using the linear- quadratic formula with overall time: BED = nd (1 + d/ [alpha/beta]) - log(e)2 (T - Tk) / alphaTp, where BED is BED = total dose x relative effectiveness (RE = nd (1 + d/ [alpha/beta]). Each of the five biologic parameters in turn was altered by +/-10%, and the altered EQD2s tabulated; the difference was finally divided by 20. EQD2 or NTD is obtained by dividing BED by the RE for 2-Gy fractions, using the appropriate alpha/beta ratio. RESULTS Variations in tumor and acute mucosal EQD ranged from 0.1% to 0.45% per 1% change in each parameter for conventional schedules, the largest variation being caused by overall time. Variations in "late" EQD were 0.4% to 0.6% per 1% change in the only biologic parameter, the alpha/beta ratio. For stereotactic body radiotherapy schedules, variations were larger, up to 0.6 to 0.9 for tumor and 1.6% to 1.9% for late, per 1% change in parameter. CONCLUSIONS Robustness occurs similar to that of equivalent uniform dose (EUD), for the same reasons. Total dose, dose per fraction, and dose-rate cause their major effects, as well known.

[1]  J. Fowler,et al.  A comment on proliferation rates in human prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[2]  D. Brizel,et al.  How much radiation is the chemotherapy worth in advanced head and neck cancer? , 2007, International journal of radiation oncology, biology, physics.

[3]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[4]  J H Hendry,et al.  Time factors in larynx tumor radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers. , 1999, International journal of radiation oncology, biology, physics.

[5]  Alexandra L Hanlon,et al.  What dose of external-beam radiation is high enough for prostate cancer? , 2007, International journal of radiation oncology, biology, physics.

[6]  A. Niemierko Reporting and analyzing dose distributions: a concept of equivalent uniform dose. , 1997, Medical physics.

[7]  J. Fowler,et al.  Is alpha/beta for prostate tumors really low? , 2001, International journal of radiation oncology, biology, physics.

[8]  J. Michalski,et al.  Impact of Elapsed Treatment Time on Outcome of External‐Beam Radiation Therapy for Localized Carcinoma of the Prostate , 2004, Cancer journal.

[9]  H. Bartelink,et al.  Fractionation in radiotherapy. , 1994, Cancer treatment reviews.

[10]  M. Sen,et al.  Altered fractionation in head and neck cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[11]  J. Fowler The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[12]  Srinivasan Vijayakumar,et al.  Technical Basis of Radiation Therapy , 2006 .

[13]  J F Fowler,et al.  Optimum overall times II: Extended modelling for head and neck radiotherapy. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  Alexandru Daşu,et al.  Should single or distributed parameters be used to explain the steepness of tumour control probability curves? , 2003, Physics in medicine and biology.

[15]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[16]  E. Horwitz,et al.  Does Total Treatment Duration Affect Outcome in Prostate Cancer Treated With Radiotherapy , 2007 .

[17]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[18]  D. Brenner,et al.  In response to Drs. King and Mayo: low α/β values for prostate appear to be independent of modeling details1 , 2000 .

[19]  Lei Dong,et al.  Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[20]  T E Schultheiss,et al.  Can modest escalations of dose be detected as increased tumor control? , 1992, International journal of radiation oncology, biology, physics.

[21]  G. Barendsen,et al.  Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. , 1982, International journal of radiation oncology, biology, physics.

[22]  W. Dörr,et al.  Consequential late effects in normal tissues. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  L. M. Mitchell,et al.  Fractionation in radiotherapy of cancer of the lip. , 2009, Acta radiologica: therapy, physics, biology.

[24]  Robert D Timmerman,et al.  Stereotactic body radiation therapy. , 2004, Current problems in cancer.

[25]  W. Dörr,et al.  Radiation-induced changes in cellularity and proliferation in human oral mucosa. , 2002, International journal of radiation oncology, biology, physics.

[26]  J. Fowler,et al.  Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  Cai Grau,et al.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial , 2003, The Lancet.

[28]  Rick Chappell,et al.  Is α/β for prostate tumors really low? , 2001 .

[29]  D. Brenner Accelerated repopulation during radiotherapy: Quantitative evidence for delayed onset , 1993 .

[30]  J. Fowler Practical Time-Dose Evaluations, or How to Stop Worrying and Learn to Love Linear Quadratics , 2011 .

[31]  D A Morgan,et al.  The role of biologically effective dose (BED) in clinical oncology. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[32]  L. Kestin,et al.  Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the α/β Ratio of Prostate Cancer , 2007 .

[33]  P Okunieff,et al.  Radiation dose-response of human tumors. , 1995, International journal of radiation oncology, biology, physics.

[34]  E. Horwitz,et al.  Does treatment duration affect outcome after radiotherapy for prostate cancer? , 2008, International journal of radiation oncology, biology, physics.

[35]  R. Tarnawski,et al.  Moderately low alpha/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[36]  Jeremy MG Taylor,et al.  Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. , 2007, International journal of radiation oncology, biology, physics.